Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab.
CONCLUSIONS: Multiorgan irAEs occurred in 5.4% of patients treated with atezolizumab in non-small cell lung cancer trials. Future trials should consider routine reporting of data on multiorgan toxicities in addition to organ-specific toxicities.
PMID: 32886899 [PubMed - as supplied by publisher]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Clinical Trials | Laboratory Medicine | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Skin | Toxicology